What Are Peptide Therapies?
Peptide therapies are a broad category of compounds being studied and used in various medical contexts. This article explains what peptides are, how they differ from FDA-approved medications, and what patients should understand about the current evidence and regulatory landscape.
What Are Peptide Therapies?
Peptide therapies have attracted significant interest in sports medicine, anti-aging medicine, and orthopedic practice. Understanding what peptides are, how they are regulated, and what the evidence actually shows is important for patients considering these treatments.
What Peptides Are
Peptides are short chains of amino acids — the building blocks of proteins. The human body produces thousands of naturally occurring peptides that serve as signaling molecules, hormones, neurotransmitters, and structural components. Insulin, for example, is a peptide hormone. Growth hormone-releasing hormone is a peptide.
Synthetic or modified peptides are compounds designed to mimic or modulate the activity of naturally occurring peptides. Some synthetic peptides have been developed into FDA-approved medications — semaglutide (Ozempic, Wegovy) is a peptide drug that is FDA-approved for type 2 diabetes and obesity. Others are being studied in clinical trials. Still others are available through compounding pharmacies without FDA approval for the specific intended use.
How Peptides Differ From FDA-Approved Medications
FDA drug approval requires the manufacturer to demonstrate safety and efficacy through a defined clinical trial process, including Phase I (safety), Phase II (dose-finding and preliminary efficacy), and Phase III (large randomized controlled trials) studies. The FDA reviews the trial data and manufacturing standards before approving the drug for a specific indication.
Compounded peptides are not FDA-approved medications. They are prepared by compounding pharmacies — either 503A pharmacies (which compound for individual patients based on a prescription) or 503B outsourcing facilities (which compound in larger batches for healthcare facilities). Compounded drugs are not required to undergo the FDA approval process, and the FDA does not review the safety and efficacy data for compounded preparations.
This does not mean compounded peptides are inherently unsafe or ineffective. It means that the level of regulatory oversight, quality control, and clinical evidence required for FDA-approved drugs does not apply to compounded peptides.
The Compounding Pharmacy Context
Compounding pharmacies prepare customized medications for patients who have a specific medical need that cannot be met by commercially available FDA-approved products. Legitimate uses of compounding include preparing medications in different dosage forms (liquid instead of tablet), removing allergens, or combining medications.
The use of compounding pharmacies to supply peptides for performance enhancement, anti-aging, or musculoskeletal healing — rather than to meet a specific unmet medical need — is a different context. The FDA has raised concerns about the use of compounding to circumvent the drug approval process for substances that have not been proven safe and effective.
What the Evidence Shows for Musculoskeletal Applications
The human clinical evidence for most peptides in musculoskeletal medicine is limited. Most published research consists of animal studies (rodent models), in vitro (cell culture) experiments, and small case series. Large randomized controlled trials in humans are largely absent for most compounded peptides used in orthopedic contexts.
This is a meaningful gap. Animal studies and cell culture experiments can generate hypotheses and identify mechanisms, but they do not reliably predict human clinical outcomes. Many compounds that show promising effects in animal models fail to demonstrate efficacy or safety in human clinical trials.
FDA Concerns About Specific Compounded Peptides
The FDA has raised specific concerns about several peptides commonly used in compounding, including BPC-157, TB-500 (thymosin beta-4 fragment), MOTS-C, and others. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed several of these compounds and considered whether they should be placed on the list of substances that cannot be compounded.
The FDA's concerns include: lack of human clinical trial data demonstrating safety and efficacy, manufacturing quality concerns, and the potential for harm from compounds that have not been adequately studied in humans.
"Made in the USA" Is Not the Same as FDA-Approved
A common marketing claim for compounded peptides is that they are "manufactured in the United States" or "made in a US-licensed pharmacy." Domestic manufacture does not confer FDA approval. The FDA approves specific drugs for specific indications based on clinical trial data — not based on where the drug is manufactured.
Patients should not interpret "made in the USA," "pharmaceutical grade," or "compounded by a licensed pharmacy" as equivalent to FDA approval.
References
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov, updated 2024.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. FDA.gov.
- Lau JL, Dunn MK. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorg Med Chem. 2018;26(10):2700–2707. DOI: 10.1016/j.bmc.2017.06.052
Reviewed by Joseph Blythe, DO — July 2026 Last medical review: July 31, 2026
Explore Topics
Written & reviewed by
Joseph Blythe, DO — Orthopedic Spine Surgeon
DO | Board-Certified Orthopedic Surgeon | Fellowship-Trained Spine Specialist
Dr. Blythe is a board-certified, fellowship-trained orthopedic and spine surgeon practicing in Oklahoma City. He completed his fellowship at the Spine Institute of Arizona and holds board certification through the American Osteopathic Board of Orthopedic Surgery (AOBO). All articles in the Patient Education Center are authored and medically reviewed by Dr. Blythe.
